Cost-effectiveness of ceftolozane/tazobactam compared to meropenem in ventilator-associated pneumonia
Abstract Introduction Ventilator-associated pneumonia (VAP) is a prominent cause of morbidity and mortality in intensive care unit patients. Ceftolozane/tazobactam could be a cost-effective treatment option prior to culture test result for treatment of VAP. This study aims to evaluate the cost-effec...
Gespeichert in:
| Hauptverfasser: | , , |
|---|---|
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
BMC
2025-10-01
|
| Schriftenreihe: | Cost Effectiveness and Resource Allocation |
| Schlagworte: | |
| Online-Zugang: | https://doi.org/10.1186/s12962-025-00658-0 |
| Tags: |
Keine Tags, Fügen Sie das erste Tag hinzu!
|